📊 FATE Key Takeaways
Is Fate Therapeutics Inc. (FATE) a Good Investment?
FATE is a pre-commercial biotech company with a structurally sound balance sheet ($39.6M cash, low leverage) but facing critical operational headwinds: revenue declined 51.2% YoY to just $1.3M, while operating cash burn of $30.8M annually provides only ~1.3 years of runway. The company must demonstrate meaningful pipeline progress and revenue stabilization to justify continued investment.
Fate Therapeutics shows weak fundamentals driven by a steep revenue decline, extremely negative operating and net margins, and heavy cash burn relative to its small revenue base. The balance sheet is still a meaningful offset, with strong liquidity, low leverage, and substantial equity supporting near-term operations. Overall, the company appears financially stable in the short term but fundamentally weak until it can improve commercialization, partnership revenue durability, or expense efficiency.
Fate Therapeutics Inc. Key Strengths (FATE)
- Strong balance sheet with $39.6M cash and minimal debt (0.08x debt-to-equity)
- Excellent liquidity position (5.85x current ratio) providing flexibility
- Improving profitability trajectory on losses (EPS improved 29.9% YoY despite negative net income)
- Strong liquidity with current and quick ratios of 5.79x
- Low leverage with debt/equity of 0.07x and only $14.00M in long-term debt
- Solid equity base of $207.18M provides near-term balance sheet support
FATE Stock Risks: Fate Therapeutics Inc. Investment Risks
- Revenue collapse of 51.2% YoY signals stalled commercialization progress, not typical early-stage growth
- Negative operating cash flow of -$30.8M with limited cash runway of ~1.3 years at current burn rate
- Company remains pre-commercial/early-stage with minimal revenue ($1.3M), indicating years away from profitability
- Revenue fell 51.2% YoY, indicating poor growth quality and weak top-line stability
- Operating margin of -2222.4% and net margin of -2051.1% reflect an unsustainable cost structure
- Free cash flow of -$112.04M and operating cash flow of -$106.08M point to continued cash runway pressure if losses persist
Key Metrics to Watch
- Revenue trajectory and pipeline advancement milestones (critical for justifying cash burn)
- Monthly cash burn rate and guidance on cash runway extension
- Clinical trial progress and regulatory approvals on lead programs
- Quarterly revenue trajectory and quality of collaboration/product revenue
- Cash burn rate versus cash and equivalents balance
Fate Therapeutics Inc. (FATE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.85x current ratio provides a solid financial cushion.
FATE Profit Margin, ROE & Profitability Analysis
FATE vs Healthcare Sector: How Fate Therapeutics Inc. Compares
How Fate Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fate Therapeutics Inc. Stock Overvalued? FATE Valuation Analysis 2026
Based on fundamental analysis, Fate Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fate Therapeutics Inc. Balance Sheet: FATE Debt, Cash & Liquidity
FATE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fate Therapeutics Inc.'s revenue has declined by 76% over the 5-year period, indicating business contraction. The most recent EPS of $-1.64 indicates the company is currently unprofitable.
FATE Revenue Growth, EPS Growth & YoY Performance
FATE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.3M | -$31.2M | $-0.26 |
| Q3 2025 | $1.7M | -$32.3M | $-0.27 |
| Q2 2025 | $1.9M | -$34.1M | $-0.29 |
| Q1 2025 | $1.6M | -$37.6M | $-0.32 |
| Q3 2024 | $1.9M | -$18.9M | $-0.40 |
| Q2 2024 | $933.0K | -$18.9M | $-0.33 |
| Q1 2024 | $1.9M | -$18.9M | $-0.19 |
| Q3 2023 | $1.9M | -$18.9M | $-0.46 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fate Therapeutics Inc. Dividends, Buybacks & Capital Allocation
FATE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fate Therapeutics Inc. (CIK: 0001434316)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FATE
What is the AI rating for FATE?
Fate Therapeutics Inc. (FATE) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FATE's key strengths?
Claude: Strong balance sheet with $39.6M cash and minimal debt (0.08x debt-to-equity). Excellent liquidity position (5.85x current ratio) providing flexibility. ChatGPT: Strong liquidity with current and quick ratios of 5.79x. Low leverage with debt/equity of 0.07x and only $14.00M in long-term debt.
What are the risks of investing in FATE?
Claude: Revenue collapse of 51.2% YoY signals stalled commercialization progress, not typical early-stage growth. Negative operating cash flow of -$30.8M with limited cash runway of ~1.3 years at current burn rate. ChatGPT: Revenue fell 51.2% YoY, indicating poor growth quality and weak top-line stability. Operating margin of -2222.4% and net margin of -2051.1% reflect an unsustainable cost structure.
What is FATE's revenue and growth?
Fate Therapeutics Inc. reported revenue of $1.3M.
Does FATE pay dividends?
Fate Therapeutics Inc. does not currently pay dividends.
Where can I find FATE SEC filings?
Official SEC filings for Fate Therapeutics Inc. (CIK: 0001434316) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FATE's EPS?
Fate Therapeutics Inc. has a diluted EPS of $-0.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is FATE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Fate Therapeutics Inc. has a C grade with 81% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is FATE stock overvalued or undervalued?
Valuation metrics for FATE: ROE of -17.4% (sector avg: 15%), net margin of -2,402.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is FATE's AI grade for 2026?
Our dual AI analysis gives Fate Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FATE's free cash flow?
Fate Therapeutics Inc.'s operating cash flow is $-30.8M, with capital expenditures of $239.0K. FCF margin is -2,391.1%.
How does FATE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,402.8% (avg: 12%), ROE -17.4% (avg: 15%), current ratio 5.85 (avg: 2).